Skip to main content

Advertisement

Table 3 Guidelines/local working group recommendations consulted for treatment of relapsed or refractory Ph(–) B-precursor ALL

From: Management and treatment of relapsed or refractory Ph(−) B-precursor ALL: a web-based, double-blind survey of EU clinicians

Guideline or local working group recommendation Number of respondents consulting for treatment n (%)a
  France Germany Italy Spain UK Total
N = 15 N = 15 N = 15 N = 15 N = 15 N = 75
ASH/ASCO, US 9 (60) 3 (20) 7 (47) 6 (40) 4 (27) 29 (39)
EWALL, Europe 7 (47) 1 (7) 2 (13) 2 (13) 7 (47) 19 (25)
NCCN, US 6 (40) 1 (7) 5 (33) 5 (33)   17 (23)
GMALL, Germany 1 (7) 13 (60) 1 (7) 1 (7)   16 (21)
GIMEMA, Italy    12 (80) 1 (7)   13 (17)
PETHEMA, Spain     11 (73) 1 (7) 12 (16)
UKALL XII, UK    1 (7)   11 (73) 12 (16)
HAS, France 2 (13)      2 (3)
Othersb 4 (27)     3 (20) 7 (9)
  1. aRespondents could select multiple guidelines
  2. bThe following guidelines and/or local working group recommendations were consulted by one respondent for treatment: COOPRALL, France; Onco LR, France; GELA, France; GRAALL, France; BCSH, UK; The Beatson hospital, UKc; UKALL 2011 for young adults, UK; non-specified protocol
  3. cThe Beatson hospital is a cancer centre located in the West of Scotland
  4. ALL, acute lymphoblastic leukaemia; ASCO, American Society of Clinical Oncology; ASH, American Society of Hematology; BCSH, the British Committee for Standards in Haematology; COOPRALL, Protocole Coopérateur de Traitement des Rechutes de Leucémies Aiguës Lymphoblastiques de L’enfant (treatment protocol for relapse of ALL in children); EWALL, European Working group for Adult Lymphoblastic Leukemia; GELA, Groupe d’Etude des Lymphomes de l’Adulte (Study Group of the Adult Lymphoma); GET-LALA, Groupe d’Etude et de Traitement des Leucémie Aiguës Lymphoblastique de l’Adulte (Group for the Study and Treatment of Adult ALL, France); GIMEMA, Gruppo Italiano Malattie EMatologiche dell’Adultodell’Adulto (Italian Group for Haematological Diseases in Adults); GMALL, German Multicenter Study Group for Adult ALL; GOELAMS, Groupe Ouest Est des Leucémies Aiguës et Maladies du Sang (East West Group of Acute Leukemia and Blood Diseases, France); GRAALL, Cooperative group combining the French GET-LALA, the GOELAMS, and the SAKK; HAS, Haute Autorité de Santé (High Authority for Health); NCCN, the National Comprehensive Cancer Network; Onco LR, le réseau régional de Cancérologie en Languedoc Roussillon (regional network of Oncology in Languedoc Roussillon); PETHEMA, Program for Study and Treatment of Malignant Haemopathies, Spanish Society of Haematology; SAKK, Schweizer Arbeitsgemeinschaft für klinische Krebsforschung, Leukämie-Arbeitsgruppe (Swiss Group for Clinical Cancer Research, Leukemia Working Group); UKALL 2011 for young adults, United Kingdom Trial for children and young adults with Acute lymphoblastic Leukaemia and Lymphoma 2011; UKALL XII, Medical Research Council Acute Lymphoblastic Leukemia Trial XII